Luke A.J. O'Neill (Inventor), Rebecca Coll (Inventor), Matthew A Cooper (Inventor), Avril A B Robertson (Inventor), Kate Schroder (Inventor), Angus Murray Macleod (Inventor), David John Miller (Inventor)

Research output: Patent


The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12alkyl, C2-C12alkenyl, C2-C12alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 and R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.
Original languageEnglish
Patent numberPCT/EP2017/053498
Priority date16/02/2016
Filing date16/02/2017
Publication statusPublished - 24 Aug 2017


Dive into the research topics of 'SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME'. Together they form a unique fingerprint.

Cite this